The Biologics Competition Act of 2023 aims to promote competition in the biologics market by allowing for the approval of interchangeable biosimilar products. It proposes provisions that streamline the regulatory process for approving these interchangeable products, which are highly similar to an already approved biologic and can be substituted for it without the intervention of a healthcare provider. This bill intends to increase access to more affordable biologic medications and foster innovation in the biopharmaceutical industry. If enacted, it could lead to lower healthcare costs and expanded treatment options for patients.
2023-03-24: Introduced in House
2023-03-24: Referred to the House Committee on Energy and Commerce.
2023-03-31: Referred to the Subcommittee on Health.
Contribute Your Insights: Add a Unique Perspective to Political Bills. Your Contribution will be Featured Below the Primary Bill, Ordered by Date Added.
No Reviews found ..